David M. Epstein - 15 Feb 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: President and Chief Executive Officer, Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol
BDTX
Transactions as of
15 Feb 2022
Transactions value $
$0
Form type
4
Filing time
17 Feb 2022, 15:19:04 UTC
Next filing
15 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +300K $0.00 300K 15 Feb 2022 Common Stock 300K $3.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Officer Title: President and Chief Executive Officer